9 Biotechnology Stocks to Sell Now

CVM, EPRS, OHRP, TSRX, SGYP, VSTM, CLDX, TRVN, AAVL slump in weekly rankings

The ratings of nine biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

CEL-SCI Corporation (CVM) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. CEL-SCI is developing new immune system based treatments for cancer and infectious diseases. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CVM also gets F’s. To get an in-depth look at CVM, get Portfolio Grader’s complete analysis of CVM stock.

This is a rough week for EPIRUS Biopharmaceuticals, Inc. (EPRS). The company’s rating falls to D from the previous week’s C. The stock also gets an F in Earnings Revisions. For more information, get Portfolio Grader’s complete analysis of EPRS stock.

The rating of Ohr Pharmaceutical Inc (OHRP) slips from a C to a D. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. To get an in-depth look at OHRP, get Portfolio Grader’s complete analysis of OHRP stock.

Trius Therapeutics, Inc. (TSRX) gets weaker ratings this week as last week’s C drops to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.

Synergy Pharmaceuticals, Inc. (SGYP) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of Sept. 4, 2015, 20.6% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. To get an in-depth look at SGYP, get Portfolio Grader’s complete analysis of SGYP stock.

Verastem, Inc. (VSTM) experiences a ratings drop this week, going from last week’s D to an F. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. As of Sept. 4, 2015, 11.2% of outstanding Verastem, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VSTM stock.

Celldex Therapeutics, Inc. (CLDX) earns a D this week, falling from last week’s grade of C. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also gets an F in Equity. As of Sept. 4, 2015, 16.9% of outstanding Celldex Therapeutics, Inc. shares were held short. To get an in-depth look at CLDX, get Portfolio Grader’s complete analysis of CLDX stock.

This week, Trevena, Inc.’s (TRVN) rating worsens to a D from the company’s C rating a week ago. The stock gets F’s in Equity and Cash Flow. Shares of the stock are being traded at a very rapid pace, up 2339.4% from the week prior. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

This week, Avalanche Biotechnologies Inc (AAVL) drops from a C to a D rating. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at AAVL, get Portfolio Grader’s complete analysis of AAVL stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/09/9-biotechnology-stocks-to-sell-now-cvm-eprs-ohrp-5/.

©2019 InvestorPlace Media, LLC